
Mineralys Therapeutics (MLYS) Financial Statements
Price: $12.4
Market Cap: $778.53M
Avg Volume: 1.01M
Market Cap: $778.53M
Avg Volume: 1.01M
Country: US
Industry: Biotechnology
Sector: Healthcare
Industry: Biotechnology
Sector: Healthcare
Overview of Financial Statements
Financial statements are records that provide an overview of a company's financial performance and position. There are three main types of financial statements:
- Income Statement: Shows the company's revenue, expenses, and profit over a specific period.
- Balance Sheet: Provides a snapshot of the company's assets, liabilities, and equity at a specific point in time.
- Cash Flow Statement: Details the cash inflows and outflows from operating, investing, and financing activities over a period.
This page presents both annual and quarterly data for these financial statements. The charts below provide a visual representation of the key metrics from each statement, helping you to quickly understand the financial health of Mineralys Therapeutics.
Income Statement
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Revenue | $- | $- | $- | $- | $- |
Cost of Revenue | $- | $- | $- | $- | $- |
Gross Profit | $- | $- | $- | $- | $- |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research and Development Expenses | $168.58M | $70.36M | $26.25M | $16.31M | $2.41M |
General and Administrative Expenses | $23.82M | $14.30M | $5.23M | $2.42M | $532.00K |
Selling and Marketing Expenses | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $23.82M | $14.30M | $5.23M | $2.42M | $532.00K |
Other Expenses | $- | $- | $4.00K | $1.00K | $-1.00K |
Operating Expenses | $192.40M | $84.66M | $31.48M | $18.73M | $2.94M |
Cost and Expenses | $- | $84.66M | $31.48M | $18.73M | $2.94M |
Interest Income | $- | $12.76M | $1.68M | $- | $- |
Interest Expense | $- | $- | $1.68M | $27.00K | $115.00K |
Depreciation and Amortization | $- | $- | $228.49K | $18.73M | $2.94M |
EBITDA | $-192.40M | $-84.66M | $-31.48M | $- | $- |
EBITDA Ratio | - | - | - | 0.00% | 0.00% |
Operating Income | $-192.40M | $-84.66M | $-31.48M | $-18.73M | $-2.94M |
Operating Income Ratio | - | - | - | - | - |
Total Other Income Expenses Net | $14.59M | $12.76M | $1.68M | $-683.00K | $-483.00K |
Income Before Tax | $-177.81M | $-71.90M | $-29.80M | $-19.41M | $-3.43M |
Income Before Tax Ratio | - | - | - | - | - |
Income Tax Expense | $- | $- | $-1.90M | $27.00K | $115.00K |
Net Income | $-177.81M | $-71.90M | $-29.80M | $-19.41M | $-3.43M |
Net Income Ratio | - | - | - | - | - |
EPS | $-3.66 | $-1.99 | $-0.73 | $-0.50 | $-0.09 |
EPS Diluted | $-3.66 | $-1.99 | $-0.73 | $-0.50 | $-0.09 |
Weighted Average Shares Outstanding | 48.54M | 36.19M | 40.86M | 39.06M | 39.06M |
Weighted Average Shares Outstanding Diluted | 48.54M | 36.19M | 40.86M | 39.06M | 39.06M |
SEC Filing | Source | Source | Source | Source | Source |
Balance Sheet
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $114.09M | $49.30M | $87.70M | $10.61M | $1.41M |
Short Term Investments | $84.10M | $187.26M | $22.41M | $- | $- |
Cash and Short Term Investments | $198.19M | $236.57M | $110.11M | $10.61M | $1.41M |
Net Receivables | $- | $- | $- | $- | $- |
Inventory | $- | $- | $- | $- | $- |
Other Current Assets | $7.16M | $12.54M | $2.70M | $460.00K | $57.00K |
Total Current Assets | $205.35M | $249.10M | $110.11M | $11.12M | $1.47M |
Property Plant Equipment Net | $53.00K | $- | $- | $- | $- |
Goodwill | $- | $- | $- | $- | $- |
Intangible Assets | $- | $- | $- | $- | $- |
Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
Long Term Investments | $- | $2.48M | $- | $- | $- |
Tax Assets | $- | $- | $- | $- | $- |
Other Non-Current Assets | $499.00K | $51.00K | $4.33M | $3.00K | $20.00K |
Total Non-Current Assets | $552.00K | $2.53M | $4.33M | $3.00K | $20.00K |
Other Assets | $- | $- | $0 | $- | $- |
Total Assets | $205.90M | $251.64M | $114.44M | $11.12M | $1.49M |
Account Payables | $479.00K | $601.00K | $1.91M | $763.00K | $529.00K |
Short Term Debt | $- | $- | $- | $- | $4.50M |
Tax Payables | $- | $- | $- | $- | $- |
Deferred Revenue | $- | $- | $- | $- | $- |
Other Current Liabilities | $14.17M | $9.88M | $6.16M | $4.29M | $54.00K |
Total Current Liabilities | $14.65M | $10.48M | $8.07M | $5.05M | $5.08M |
Long Term Debt | $- | $- | $- | $- | $- |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
Other Non-Current Liabilities | $- | $- | $- | $- | $- |
Total Non-Current Liabilities | $- | $- | $158.64M | $29.00M | $- |
Other Liabilities | $- | $- | $- | $- | $- |
Total Liabilities | $14.65M | $10.48M | $166.71M | $34.05M | $5.08M |
Preferred Stock | $- | $- | $158.64M | $29.00M | $- |
Common Stock | $5.00K | $4.00K | $1.00K | $1.00K | $1.00K |
Retained Earnings | $-302.52M | $-124.71M | $-52.81M | $-23.01M | $-3.60M |
Accumulated Other Comprehensive Income Loss | $- | $- | $-158.64M | $-0 | $0 |
Other Total Stockholders Equity | $493.77M | $365.86M | $52.81M | $-29.00M | $5.00K |
Total Stockholders Equity | $191.26M | $241.15M | $-52.27M | $-22.93M | $-3.60M |
Total Equity | $191.26M | $241.15M | $-52.27M | $-22.93M | $-3.60M |
Total Liabilities and Stockholders Equity | $205.90M | $251.64M | $114.44M | $11.12M | $1.49M |
Minority Interest | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $205.90M | $251.64M | $114.44M | $11.12M | $1.49M |
Total Investments | $84.10M | $189.75M | $22.41M | $- | $- |
Total Debt | $- | $- | $- | $- | $4.50M |
Net Debt | $-114.09M | $-49.30M | $-87.70M | $-10.61M | $3.09M |
Cash Flow Statement
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Net Income | $-177.81M | $-71.90M | $-29.80M | $-19.41M | $-3.43M |
Depreciation and Amortization | $43.00K | $- | $- | $- | $- |
Deferred Income Tax | $- | $- | $- | $- | $- |
Stock Based Compensation | $11.34M | $5.06M | $455.00K | $80.00K | $1.00K |
Change in Working Capital | $9.52M | $-7.47M | $772.00K | $4.08M | $480.00K |
Accounts Receivables | $424.00K | $- | $- | $- | $- |
Inventory | $- | $- | $- | $- | $- |
Accounts Payables | $- | $- | $3.01M | $- | $- |
Other Working Capital | $9.10M | $-7.47M | $772.00K | $4.08M | $480.00K |
Other Non Cash Items | $-9.40M | $-6.87M | $-649.00K | $684.00K | $482.00K |
Net Cash Provided by Operating Activities | $-166.31M | $-81.17M | $-29.22M | $-14.56M | $-2.46M |
Investments in Property Plant and Equipment | $-96.00K | $- | $- | $- | $- |
Acquisitions Net | $- | $- | $- | $- | $- |
Purchases of Investments | $-373.44M | $-347.97M | $-71.76M | $- | $- |
Sales Maturities of Investments | $488.50M | $187.50M | $50.00M | $- | $- |
Other Investing Activities | $- | $- | $-21.76K | $- | $- |
Net Cash Used for Investing Activities | $114.96M | $-160.47M | $-21.76M | $- | $- |
Debt Repayment | $- | $- | $- | $- | $- |
Common Stock Issued | $116.06M | $202.99M | $- | $23.81M | $-20.00K |
Common Stock Repurchased | $- | $- | $-1.63M | $- | $-20.00K |
Dividends Paid | $- | $- | $- | $- | $- |
Other Financing Activities | $83.00K | $516.00K | $129.65M | $23.81M | $3.83M |
Net Cash Used Provided by Financing Activities | $116.14M | $203.25M | $128.02M | $23.81M | $3.83M |
Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
Net Change in Cash | $64.79M | $-38.40M | $77.04M | $9.25M | $1.37M |
Cash at End of Period | $114.09M | $49.30M | $87.70M | $10.66M | $1.41M |
Cash at Beginning of Period | $49.30M | $87.70M | $10.66M | $1.41M | $42.00K |
Operating Cash Flow | $-166.31M | $-81.17M | $-29.22M | $-14.56M | $-2.46M |
Capital Expenditure | $-96.00K | $- | $- | $- | $- |
Free Cash Flow | $-166.41M | $-81.17M | $-29.22M | $-14.56M | $-2.46M |